Solid Biosciences Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| SLDB | DSGN | OBIO | EWTX | RCKT | LXEO | |
|---|---|---|---|---|---|---|
| Market cap | 699.11M | 665.24M | 360.63M | 4.08B | 286.51M | 265.14M |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | -3.8 | -6.6 | -4.0 | -20.1 | -1.6 | -2.4 |
| Price/book | 2.9 | 3.0 | 18.7 | 7.6 | 0.8 | 1.1 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | +59.80% | +57.86% | +41.84% | +119.60% | −24.40% | −62.07% |
| Today | +3.82% | +2.80% | +7.91% | −0.40% | +3.98% | +3.86% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All SLDB news ›UBS initiated coverage on Solid Biosciences with a new price target
Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. UBS initiated coverage on Solid…
Solid Biosciences Announces European Commission Orphan Designation for SGT-212 and Continued Progress in the FALCON Trial in Friedreich’s Ataxia
- Obtaining Orphan designation from the European Commission reflects Solid’s commitment to the global development of SGT-212 for individuals living with Friedreich’s ataxia - - SGT-212 is a first-in-class dual route FA gene therapy…
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CHARLESTOWN, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ:SLDB) (the "Company"), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced a grant of…
Solid Biosciences (NASDAQ:SLDB) Insider Sells $24,581.88 in Stock
Posted by Tristan Rich on Oct 23rd, 2026 SLDB stock opened at $6.19 on Friday. Solid Biosciences Inc. has a twelve month low of $3.79 and a twelve month high of $11.45. The firm’s fifty day simple moving average is $8.20 and its…
Solid Biosciences to Present Research Across Gene Therapy Development, Delivery and Manufacturing at ESGCT 2026
CHARLESTOWN, Mass., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ:SLDB) (the "Company" or "Solid"), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced…
Solid Biosciences (SLDB): Chief Medical Officer Brooks Gabriel sold $24,582 worth of shares (4,374 units at $5.62) as part of a pre-agreed trading plan (SEC Form 4)
Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Solid Biosciences (SLDB): Chief…
Solid Biosciences Reports Third Quarter 2026 Financial Results and Provides Business Updates
Q3 net loss $53.9M ($0.36/sh) vs $45.8M y/y; SGT-003 FDA Type C meeting late Q4 on accelerated approval; cash $348.9M into H1 2028. Plus members following SLDB get this by push and email at 16:07:22 ET - it reached us under a second after…
SLDB: SEC Form 4 filed by Solid Biosciences Inc.
Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. SLDB: SEC Form 4 filed by Solid…
Solid Biosciences to Participate at Upcoming Investor Conferences
CHARLESTOWN, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ:SLDB) (the "Company" or "Solid"), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- globenewswire.com1
- manilatimes.net1
- themarketsdaily.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 3 articles, not a forecast.